What Vastarel-MR Treats: Main Uses and Benefits

Vastarel-MR is used to provide symptomatic support in situations involving certain distressing symptoms. The medicine is used for the symptomatic treatment of stable angina pectoris.

---

Symptomatic Management for Stable Angina Pectoris

This medicine is commonly used to help with conditions characterized by periods of heightened symptoms. It is relevant when supportive symptom management is appropriate, particularly when additional symptomatic support is needed. It is applied in clinical settings that involve acute or unstable symptom patterns, where appropriate. It is relevant in situations involving recurrent or episodic manifestations.

---

Contributes to Easing Overall Symptom Burden

Applied in scenarios where additional management of physical discomfort is required, Vastarel-MR helps address symptom clusters that interfere with daily comfort. It provides support that helps ease the overall symptom load, contributing to improved comfort during symptomatic periods. It helps support general well-being during symptomatic phases.

“It offers symptomatic relief that may help patients cope more steadily with difficult episodes.”

• Quick Fact: Relief for Physical Discomfort

Official Eligibility Profile for Vastarel-MR

Eligibility for Vastarel-MR (Trimetazidine) is strictly defined by regulatory authorities and centers on patient age, existing neurological conditions, and organ function. The medicine is officially approved for use only in adults as an add-on symptomatic therapy for stable angina pectoris.

Populations Who Must Not Use Vastarel-MR (Contraindications)

Condition	Regulatory Status	Status Detail
Movement Disorders	Contraindicated	Patients with Parkinson disease, parkinsonian symptoms, tremors, or restless leg syndrome.
Severe Renal Impairment	Contraindicated	Patients with severe kidney problems (creatinine clearance < 30 mL/min).
Hypersensitivity	Contraindicated	Patients with known allergy to trimetazidine or any excipients.

Restricted and Not Recommended Use

The medicine is not recommended for the following groups due to lack of established safety or efficacy data:

• Pediatric Population: Use is not recommended for children and adolescents under 18 years old.
• Pregnancy and Lactation: Use is not recommended and should be avoided in pregnant and breastfeeding women.

Caution is specifically required for patients over 75 years and those with moderate renal impairment (creatinine clearance 30 – 60 mL/min), often requiring special consideration.

Interactions with other medicines and products

Official regulatory documents state that no drug interactions have been identified with Vastarel-MR (trimetazidine modified release). This means that the regulatory assessment concluded that co-administering Vastarel-MR with other commonly used medicinal products is not expected to cause a clinically significant change in its effectiveness or safety profile due to drug-drug interactions.

Regulatory authorities specifically evaluate potential interactions to determine if co-administration requires adjustments, increased monitoring, or avoidance. In the case of Vastarel-MR, the official labeling does not include a list of interacting medicines, product classes, or timing-based conditions that must be followed due to interaction concerns.

Despite the lack of identified drug interactions, general medical guidance suggests that caution is warranted when Vastarel-MR is used in certain patient populations. For instance, increased exposure to the drug is anticipated in patients with moderate kidney impairment and in the elderly population (over 75 years of age). This note is not an interaction per se, but a necessary consideration for these specific patient groups. Therefore, no formal constraints or restrictions related to drug interactions are documented in the official regulatory information for Vastarel-MR.

The mechanism of action for Trimetazidine is strictly metabolic and cytoprotective. The mechanism is centered on inducing a metabolic state that increases cellular resilience against low oxygen conditions (ischemia). The action is purely metabolic and does not directly alter systemic hemodynamic parameters such as heart rate or blood pressure.

Metabolic Modulation and Oxygen Sparing

This domain covers the drug’s primary molecular target: the enzyme Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase (LC 3-KAT). Trimetazidine acts as a reversible inhibitor of LC 3-KAT, partially suppressing the heart muscle's use of fatty acids for energy. This action forces a shift toward the more oxygen-efficient Glucose Oxidation, which creates an Oxygen Sparing Effect by requiring less oxygen to generate the same level of cellular energy (ATP).

Stabilization of Intracellular Ion Homeostasis

This cascade is a significant downstream effect of the metabolic shift. By reducing the reliance on fatty acids, the drug prevents the accumulation of acidic byproducts ( H^+) that typically disrupt ion regulation during stress. This preserved pH stability limits the dysfunction of membrane exchangers, preventing the toxic buildup of sodium ( Na^+) and the subsequent calcium ( Ca^2+) overload, which influences factors that preserve the capacity for mechanical function and supports the structural stability of myocardial tissue.

Official Administration Guidelines for Vastarel-MR

The standard protocol for Vastarel-MR (Trimetazidine 35 mg modified-release) establishes a specific procedural structure for its use, defining the route, dosing schedule, and required adjustments.

Instruction	Detail
Route of Administration	Oral route.
Standard Dosing Schedule	One 35 mg tablet per dose.
Standard Frequency	Twice daily (b.i.d.), taken in the morning and evening.
Timing in Relation to Meals	Must be taken during meals.
Preparation Requirement	The modified-release tablet must be swallowed whole and must not be chewed or crushed.

Population and Procedural Adjustments

Special Condition	Procedural Instruction
Moderate Renal Impairment	Dose must be reduced to one 35 mg tablet, once daily (o.d.), taken with the morning meal.
Older Adults	Caution in dose titration is mandated due to age-related decline in kidney function.
Pediatric Use	Use in individuals under 18 years of age is not recommended.
Missed Dose	Treatment should be resumed with the next scheduled dose; the dose should not be doubled.
Treatment Review	The benefit of the therapy must be assessed after three months of continuous use, with discontinuation advised if no response is demonstrated.

Connection to the overall use protocol: Standard guidelines establish a high-level protocol for the administration of Vastarel-MR that centers on a specific modified-release formulation. This protocol dictates the exact frequency and context necessary for proper use, while also explicitly defining dose modifications based on the patient's renal function status. The structure formalizes the procedural requirements and includes a mandatory review period for continuous therapy.

Vastarel-MR: Recent Clinical Evidence

Evidence for Symptom Management in Stable Angina Pectoris

Research exploring this area includes short-term randomized controlled trials (RCTs). These studies were often controlled against a placebo (an inactive substance) or were designed to examine the medicine when added to a patient's existing conventional treatment. In these research scenarios, studies monitored outcomes related to physical discomfort, primarily looking at the weekly frequency of angina attacks and the consumption of short-acting nitrates (rescue medication). The findings describe patterns observed in the studies where differences were reported in the weekly frequency of angina attacks and the consumption of short-acting nitrates between the medicine and comparator groups.

Comparison Studies and Placebo-Controlled Evidence

The research has explored the medicine’s use when applied in studies examining patient-reported experiences alongside existing therapies. The evidence derived from these settings suggests that in studies where Vastarel-MR was added to standard anti-anginal drugs, studies report how symptoms evolved in the observed populations. Research has explored whether the medicine may be relevant when standard treatment alone was insufficient to control episodic or acute changes in symptoms. Because much of the evidence relies on this add-on research design, the data largely show patterns related to its use in combination with other treatments, rather than as a primary stand-alone therapy.

Long-Term Research and Durability of Response

Research has also examined the medicine over more extended periods. While the primary efficacy trials were often conducted over just eight to twelve weeks, observational studies and select longer-term trials have been applied in studies examining patient-reported experiences up to several months or even years. These longer research scenarios primarily monitored outcomes monitoring physiological strain or stress, particularly outcomes related to major adverse cardiac events (MACE) and mortality. However, long-term effects are not fully established; findings were mixed or inconsistent regarding the influence on these very long-term, structural endpoints.

Research in Specific Patient Groups

The research for Vastarel-MR has explored specific populations, including those with conditions where symptoms may vary in intensity alongside coexisting health issues. This medicine was evaluated in studies that included adult patients with stable angina who also had comorbidities like Type 2 Diabetes Mellitus and Hypertension. The results apply only to the populations studied. Data for certain groups, such as children or pregnant populations, remain insufficient in the evidence base.

Key Limitations and Unanswered Questions

Certainty remains low regarding the medicine’s impact on hard clinical outcomes, such as the long-term risk of cardiac mortality or major adverse events. The evidence highlights that follow-up durations were limited in the trials that provided core symptomatic data. Furthermore, while the research provides insight into short-term changes, comparative evidence is lacking for long-term outcomes. Research provides context but not individual predictions, and the evidence base continues to evolve.

Common questions about Vastarel-MR (FAQ)

Q: Are there any specific food restrictions while using Vastarel-MR?

A: Official regulatory information does not list any specific food restrictions or interactions with food that need to be avoided. However, the product information describes taking the tablet in the context of meals. This context is part of the overall usage protocol documented by regulators.

Q: Is Vastarel-MR a type of beta-blocker or calcium channel blocker?

A: No, Vastarel-MR is classified as a metabolic anti-ischemic agent. Regulatory documents state that it works through a cytoprotective, metabolic pathway to help heart cells use oxygen more efficiently. It does not directly affect systemic parameters like heart rate or blood pressure, which is how beta-blockers and calcium channel blockers primarily work.

Q: Can Vastarel-MR affect a person's ability to drive or operate machinery?

A: Yes, official warnings advise caution. This medicine may cause side effects such as dizziness or drowsiness, which could affect a person’s ability to drive or safely use machinery. The official product information notes the potential for these effects, particularly prior to engaging in activities that require focus and coordination.

Q: Does official research show that Vastarel-MR improves quality of life?

A: Research supporting the medicine’s use has included studies examining patient-reported outcomes. Evidence suggests that in some trials, particularly when used as an add-on therapy, the medicine was associated with an improvement in measures related to the patient’s quality of life.

Q: Are there specific tests that are done before or during treatment with Vastarel-MR?

A: Yes, regulatory information indicates that specific medical tests may be required. This is particularly true for kidney function tests (creatinine clearance), and the regulatory information notes that dose modifications or contraindications are based on the results of these tests.

Q: What does the drug's regulatory information say about discontinuation syndrome?

A: The official documents do not use the specific term 'discontinuation syndrome.' However, they do specify that if a patient develops Parkinsonian symptoms (such as tremors or gait instability), these symptoms are usually reversible and often resolve within four months after discontinuing the medicine.

Q: Can Vastarel-MR be used for vertigo or dizziness?

A: The only official indication described in current regulatory documents is its use as an add-on symptomatic therapy for adults with stable angina pectoris (chest pain). Its use is strictly limited to this approved condition.

Q: Is weight gain a possible side effect of Vastarel-MR?

A: Weight gain is not listed as a common, rare, or known frequency side effect in the official regulatory documents for this medicine. Side effects that are documented fall into categories such as neurological or gastrointestinal issues.

Q: What happens if a person stops taking Vastarel-MR suddenly?

A: Official documents only specify that the most serious adverse effects, specifically Parkinsonian symptoms, are usually reversible upon discontinuation of the medicine. No other general sudden cessation effects are detailed in the official safety information.

Q: Is Vastarel-MR an older drug or a relatively new treatment?

A: The active ingredient, Trimetazidine, has a long history. Regulatory records indicate that the substance was first approved in Japan in 1968, positioning it as an established medicine, although specific formulations have evolved over time.

Q: Are there different strengths of Vastarel-MR available?

A: The specific modified-release (MR) form of Vastarel is typically supplied as a 35 mg tablet. Other strengths of the active ingredient (Trimetazidine) may be available, but they are generally supplied in different, non-MR formulations.

Q: Is it normal to feel a tingling sensation when starting Vastarel-MR?

A: A tingling or crawling sensation, known as paresthesia, is a potential adverse effect that has been documented in the regulatory safety information for this medicine. The regulatory information documents this as a possible effect.

Q: Are there certain heart rhythm conditions where Vastarel-MR is not recommended?

A: Official regulatory information does not list pre-existing heart rhythm conditions as a specific contraindication for using this medicine. The strict contraindications focus on patients with movement disorders (Parkinsonian symptoms) and severe renal impairment (kidney issues).

Q: Is a metallic taste in the mouth listed as a possible side effect of Vastarel-MR?

A: Metallic taste (dysgeusia) is not listed as a documented side effect in the official frequency tables of the medicine's regulatory information. The most common side effects involve the nervous system and gastrointestinal tract.

Q: What is the difference between Vastarel-MR and other metabolic agents?

A: The medicine’s difference lies in its unique mechanism of action. It works by selectively inhibiting the enzyme Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase (LC 3-KAT), which leads to an oxygen-sparing effect by favoring glucose oxidation for cell energy.

Q: Are there any documented cases of severe allergic reactions to Vastarel-MR?

A: Official documents include hypersensitivity to the active ingredient as a contraindication. Severe symptoms such as swelling of the face, lips, tongue, or throat (potential signs of severe allergic reaction) are documented as adverse effects, although their frequency is classified as 'not known.'

Storage and Disposal of Vastarel-MR

This medicine must be stored and disposed of according to official regulatory requirements to maintain its stability and ensure public safety.

Official Storage Requirements

Vastarel-MR must be stored at a temperature not exceeding 30 C and should not be refrigerated. The product must be kept in its original package to protect from moisture. It is a mandatory requirement to keep the tablets out of the sight and reach of children.

Disposal Instructions

Do not use the medicine after the expiry date printed on the packaging. Unused or expired tablets should not be disposed of via household waste or wastewater. Individuals must ask a pharmacist or follow local regulations for the proper disposal of the unused product.